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IL-6 excess is central to the pathogenesis of multiple inflammatory conditions and is targeted in clinical practice by
immunotherapy that blocks the IL-6 receptor encoded by IL6R. We describe two patients with homozygous mutations in IL6R
who presented with recurrent infections, abnormal acute-phase responses, elevated IgE, eczema, and eosinophilia. This study
identifies a novel primary immunodeficiency, clarifying the contribution of IL-6 to the phenotype of patients with mutations in
IL6ST, STAT3, and ZNF341, genes encoding different components of the IL-6 signaling pathway, and alerts us to the potential
toxicity of drugs targeting the IL-6R.
The central role of IL-6 in the pathogenesis of inflammatory
conditions such as rheumatoid arthritis, juvenile idiopathic
arthritis, and giant cell arteritis is confirmed by the efficacy of
tocilizumab, an anti–IL-6R antibody (Tanaka et al., 2018). IL-6
interacts with a multi-subunit receptor complex, initially by the
binding of IL-6 to the 80-kD receptor (IL-6R), which exists in
either membrane-bound or soluble forms. The IL-6/IL-6R com-
plex ligates the signal-transducing subunit, glycoprotein 130
(GP130), leading to a wave of receptor, JAK, and STAT phos-
phorylation and culminating in the nuclear import of phos-
phorylated STAT (pSTAT) dimers, predominantly STAT3, that
activate transcription, leading to growth and cellular differen-
tiation (Taga and Kishimoto, 1997).
While the consequences of excessive IL-6 signaling in hu-
mans have been well established, the consequences of impair-
ment have been more elusive. Reports of disease-causing
neutralizing IL-6 antibodies have been informative (Puel et al.,
2008); however, those reports would benefit from the corrob-
oration and specificity that the study of genetic loss provides.
Loss-of-function (LOF) mutations affecting GP130 and STAT3
lead to multisystem disorders encompassing IgE elevation, in-
fection susceptibility, and connective tissue abnormalities
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(Grimbacher et al., 1999; Schwerd et al., 2017); however, the
specific contribution of IL-6 remains undefined. Studies of pa-
tients with loss of IL-6R function therefore provide a unique
opportunity to establish the role for IL-6 in these disorders and
define how impaired IL-6 signaling impacts human health.
Results and discussion
Clinical findings
We identified two patients with atopic dermatitis, elevated IgE,
reduced inflammatory responses, and recurrent skin and lung
infections. Patient 1 (P1; 29-yr-old female), who was born to
white English parents of European ancestry without known
consanguinity, initially presented with neonatal mastitis. She
suffered from recurrent sinopulmonary infections including
Haemophilus influenza pneumonia and recurrent deep staphylo-
coccal skin infections. She also suffered from asthma and
moderate atopic dermatitis, affecting lower legs, thighs, but-
tocks, and elbows. The dermatitis was associated with extensive
subcutaneous nodules that were intensely pruritic, and persis-
tent scratching led to development of deep excoriations on legs,
buttocks, arms, shoulders, and scalp. Apart from one episode of
impetiginized varicella infection in her first year, no significant
viral infections were noted. Total IgE level was elevated, with
the highest recorded level being 7,060 kU/liter (normal 0–81 kU/
liter). She had mildly reduced IgG, IgA, and IgM. A striking
feature was a lack of clinically adequate inflammatory response
in the face of marked infection. While she did develop minor
nontender lymphadenopathy in a number of infections, her
abscesses were notable for their lack of erythema (Fig. 1 A) and
pyrexia. A recordable fever was observed on only two occasions,
throughoutmultiple inpatient admissions for systemic infection.
In addition, the peripheral neutrophil response was typically
minimal in proportion to her illnesses, and infectious episodes
were more marked by eosinophilia than neutrophilia (Fig. 1 B).
Further, despite gross elevations in serum IL-6 levels (Table 1),
which stimulates the serological acute phase response (Majello
et al., 1990; Hutchinson et al., 1994), C-reactive protein (CRP)
was never detectable during infection or convalescence on
standard diagnostic assay (detection level 0.175 mg/liter). Pa-
tient 2 (P2; 15-yr-old male) was born to consanguineous parents
of Pakistani origin. From 6 mo of age, he suffered from
relapsing-remitting, itchy, eczematous skin lesions (with no
other history of clinical allergy, severity scoring of atopic der-
matitis: 61.85) which weremanaged with topical fusidic acid and
betamethasone (Fig. 1 C). The family history was remarkable for
the early deaths of a sibling and a cousin, whowere both affected
by similar skin lesions, but no further details are known. In his
first 2 yr of life, P2 had recurrent upper respiratory tract in-
fections and two pneumonias, requiring hospitalization and i.v.
antibiotic treatment. At age 10, he developed a methicillin-
resistant Staphylococcus aureus psoas abscess requiring surgical
drainage. He also had recurrent skin abscesses; however, his
CRP was barely above the limits of detection (highest recording
2.1 mg/liter), even during acute inflammatory episodes. Serum
biochemical parameters and liver and kidney function tests
were within normal limits. No viral or fungal infections were
noted. Neutrophilia was observed in blood counts during ab-
scess episodes, and IgG, IgA, and IgM levels were mildly re-
duced; in contrast, IgE was elevated (787 kU/liter, normal
range 0–100 kU/liter). At present, he receives regular i.v.
immunoglobulin replacement and antibiotic prophylaxis, al-
leviating his symptoms.
Amore detailed patient history for P1 is provided inMaterials
and methods. The results of clinical laboratory testing, including
immunoglobulin levels and lymphocyte subsets from both pa-
tients, are provided in Table 1.
Genetic and functional assessment
Assessment of common single-nucleotide polymorphisms in the
whole-genome sequencing (WGS) data of P1 demonstrated a rare
genetic anomaly: chromosome 1 (C1) contained only homozy-
gous variants (Fig. 1 E). Since read depth was even across all
chromosomes (excluding large genomic deletions), the C1 loss of
heterozygosity is explained by uniparental isodisomy, when
both homologous chromosomes are inherited from the same
parent. C1 contained a set of rare coding homozygous variants
(Table S2) with one priority candidate: a 1-bp frameshift deletion
(NM_000565.3:c.548delG; p.G183Efs*7) in exon 4 of the IL6R
gene (Fig. 1 F) that leads to a premature stop codon. For P2,
whole-exome sequencing identified two homozygous missense
variants in exon 6 of IL6R (ENST00000368485.3:c.836T>A,
p.I279N, combined annotation-dependent depletion [CADD]
score 24.8, and ENST00000368485.3:c.839A>C, p.H280P, CADD
score 10.5). Both variants were ultrarare, had high CADD scores
(Fig. 1 D), relative to previously observed homozygous IL6R
variants, and are predicted to be damaging because their CADD
scores are above the mutation significance cutoff (Itan et al.,
2016) of 3.313 (the lower 99% CI of CADD-based mutation sig-
nificance cutoff for IL6R variants, estimated using pathogenic
mutations reported in Human Gene Mutation Database and
ClinVar). The H280 amino acid is at (and the I279 adjacent to)
the face of IL-6R’s D2 convex bulge that docks into the D3 do-
main of GP130. Since this interface is necessary for the IL-6/IL-
6R complex’s GP130 affinity (Boulanger et al., 2003), disruption
due to amino acid substitution at these sites could limit IL-6
signaling. Both variants were confirmed by Sanger sequencing
and appropriately segregated under the assumption of autoso-
mal recessive inheritance (Fig. 1, F and G). The candidate var-
iants in P1 and P2 (Fig. 1 H) are novel and not found in the
aggregate 150,000 human genomes available from the Genome
Aggregation Database (gnomAD), Trans-Omics for Precision
Medicine, and National Institute for Health Research (NIHR)
BioResource–Rare Diseases (NBR-RD).
We next tested the effect of the mutations on the expression
and function of IL-6R. The homozygous premature stop of P1 led
to reduced surface IL-6R expression on CD45RO+ memory CD4+
T cells and CD27−memory CD4+ T cells, in comparison to healthy
control expression (Fig. 1 I). By contrast, surface IL-6R expres-
sionwas present on peripheral blood lymphocytes of P2 (Fig. 1 J).
Despite P2’s normal receptor expression, IL-6–mediated phos-
phorylation of STAT3 and STAT1 proteins was absent in P1 and
barely detectable in P2, contrasting with a normal response to
IL-27 and IL-21 stimulation (Fig. 2, B–D). GP130 expression on
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peripheral blood lymphocytes of P1 was actually increased
compared with control (Fig. 2 A), likely due to the absence of IL-
6–mediated down-regulation (Wang et al., 1998). This result
therefore additionally demonstrates that a level of tonic IL-6
signaling occurs in healthy controls. Given that IL-6 and IL-27
both signal through GP130 (Zhong et al., 1994; Pflanz et al.,
2004), the STAT-signaling data confirmed normal GP130 sig-
nal transduction and localized the lesion to IL-6R in both
patients.
To demonstrate that the lack of IL-6R in P1 causes the absent
IL-6–pSTAT response, an expression construct with WT IL-6R
was transfected into the peripheral blood mononuclear cells
(PBMCs) of P1 and healthy controls, demonstrating equal surface
IL6R expression (Fig. S1) and restoring IL-6–dependent phos-
phorylation of STAT3 and STAT1 (Fig. 2 E). To investigate the
pathogenicity of the two homozygous variants identified in P2,
because of the limited primary tissue available, HEK293 cells
were used. As two homozygous variants had been identified, to
identify which was the causative mutation, cells were trans-
fected with WT, p.I279N, p.H280P, or p.I279N/p.H280P vectors
(the latter including both variants in the same plasmid). IL-
6–induced STAT1 and STAT3 phosphorylation was deficient in
p.I279N-transfected cells, whereas the responses were normal in
WT and p.H280P transfectants, demonstrating that the p.I279N
variant, rather than p.H280P variant, was pathogenic (Fig. 2 F).
Of note, while an I279D substitution completely abrogated IL-6
binding to IL-6R (Yawata et al., 1993), staining for IL-6R in
transfected cells showed that although Flag-tagged protein levels
were equivalent in I279N and WT, IL-6R staining was substan-
tially reduced (Fig. S1). The discrepancy in surface staining be-
tween the ex vivo and transfected cells could be explained by the
presence of soluble IL-6R bound to patient PBMCs, which could
contribute to the normalized staining ex vivo, whereas the
transfection experiments express only membrane-bound IL-6R.
There could also be other posttranscriptional processing differ-
ences in the overexpression system which may be altered
uniquely by the I279N mutation.
Immunophenotyping
The above results defining P1 as IL-6R null and P2 with protein-
positive IL-6R-LOF provided a unique opportunity to investigate
the contribution of IL-6 to the immunological phenotype. Single-
cell RNA sequencing (RNA-seq) of mononuclear cells isolated
from P1 compared with a normal familial control showed an
increased proportion of memory CD4+ T cells expressing T
helper 2 (Th2)–associated GATA3, as well as higher expression
levels of GATA3 (Fig. S2) (Fig. 3 A). Similar results were ob-
served via real-time PCR measurement of GATA3 expression in
P1 PBMCs (Fig. 3 B), as well as activated naive CD4 T cells
(Fig. 3 D). P1 had reduced numbers of class-switched memory
B cells, and within this population a higher proportion of IgE-
and IgG4-expressing B cells was found (Fig. 3 A). P1 also had an
increased proportion of FOXP3+ regulatory T cells, with in-
creased relative expression of FOXP3 (Fig. 3 A), and this was
confirmed on flow cytometry (Fig. 3 C). Interestingly, P1 naive
CD4+ T cell precursors poorly up-regulated IL17A compared with
controls (Fig. 3 A), under all conditions. Induction remained
impaired in cultures with IL-23 and IL-21, despite the observa-
tion that IL-23 and IL-21 led to a normal increase in the ex-
pression of RORC, T-bet, and IFNγ (Fig. 3 D). The impairment
was present even in the condition of IL-23 addition without IL-6,
potentially because IL-23R must be up-regulated by a STAT3
agonist (de Wit et al., 2011). The impairment was not due to a
global transcriptional unresponsiveness to these cytokines since,
in addition to the RORC up-regulation, the fold increase with
stimulation was comparable to controls, despite the lower ab-
solute basal and induced levels of STAT3-target, SOCS3, induced
by IL-21, IL-23, and IL-27 (Fig. 3 E). These results demonstrate a
nonredundant role for IL-6 in the in vitro induction of the ex-
pression of IL17A, but not RORC from naive precursors. It is likely
that in vivo, given the presence of Th17 cells and absence of
fungal infections dependent on IL-17, there are redundant cy-
tokines that allow for Th17 differentiation in the absence of IL-6
signaling.
We proceeded to confirm which aspects of P1’s phenotype
were shared with P2. While both patients and controls had
comparable production of IL-17A, they both had reduced pro-
duction of IFNγ (Fig. 4 A). The elevated GATA3 seen in the
single-cell, PBMC, and naive T-cell induction experiments from
P1 was not associated with increased CCR4+ (correlated to Th2
cells) levels, or any striking increase in the production of Th2
cytokines IL-4 or IL-13 ex vivo (Fig. S3). However, pathological
effector Th2 cells, which are more closely associated with Th2-
associated tissue pathology (Mitson-Salazar et al., 2016; Wambre
et al., 2017), were elevated in both patients, although more
markedly in P1, consistent with the higher IgE (Fig. 4 B). While
an expansion of such proatopic T cells is consistent with the
clinical phenotype, this result appears initially surprising be-
cause of data implicating IL-6 in generating Th2 cells (Rincón
et al., 1997) and promoting IgE class switching (Vercelli et al.,
Figure 1. Skin lesions, pedigrees, genetic sequencing results, and IL-6R expression levels in two patients with immunodeficiency, atopy, and
abnormal inflammatory responses. (A) Photographs of the skin lesions of P1 demonstrating the excoriation and skin-colored nontender subcutaneous
nodules (top) and a typical abscess (bottom) with the notable lack of surrounding erythema. (B) P1 diagnostic laboratory measurements of CRP and neutrophil
and eosinophil count measured during multiple infective episodes over a 3-yr period. Normal ranges: CRP <5 mg/liter, neutrophils 1.7–6.5 × 109/liter, eosi-
nophils 0.04–0.5 × 109/liter. (C) Photograph of the excoriating eczematous dermatitis found on the lower extremities of P2. (D) CADD/MAF graph of the
variants identified in the IL6R gene of P2, plotted with the variants in the populations extracted from the databases ExAC and gnomAD. (E) Plot of read depth
and zygosity at 23,368 genome-wide autosomal SNV positions in P1’s WGS data. Red dots, homozygous SNV calls; blue dots, heterozygous SNV calls. (F and G)
The pedigrees, dideoxy sequencing chromatograms, and IL-6R mutations of P1 (F) and P2 (G). (H) Schematic representation of the IL-6R protein together with
the positions of the mutations identified in P1 and P2. (I) Left: Fluorescence histograms of IL-6R expression within the memory (CD45RO+) and naive
(CD45RO−) populations of gated CD3+CD4+ T cells from P1. Right: Dot-plots of IL-6R and CD27 of gated CD3+CD4+ T cells from P1. (J) Fluorescence histograms
of IL6R expression on CD4+ and CD8+ T cells and B cells (CD19+) of P2. HC, healthy control.
Spencer et al. Journal of Experimental Medicine 1989
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1989; Jabara et al., 1990). However, STAT3 activation leads to the
expression of and physical binding to ERBIN, encoded by the
gene ERBB2IP, which limits TGF-β signaling by cytoplasmic se-
questering of the SMAD2/3 components and normally prevents
expression of IL-4Rα on naive CD4+ T cells and B cells, re-
straining Th2 responses (Lyons et al., 2017). Corroborating this
was the observation that P1’s IL4R expression was elevated in
these cell types in the single-cell RNA-seq analysis (Fig. S3). So,
IL-6 may have opposing roles in Th2 responses, in that it can
promote IL-4 transcription (Diehl et al., 2002) and IgE class
switching but could prevent IL-4 receptor expression by block-
ing TGF-β signaling.
In animal models, IL-6 is essential for circulating T follicular
helper (cTFH) cell induction (Eto et al., 2011) and the observation
of decreased cTFH cells in patients with STAT3-LOF (Ma et al.,
2016) prompted this assessment in P1 and P2. Both patients had a
reduced percentage of cTFH cells compared with healthy con-
trols (Fig. 4 C). Furthermore, IL-6 (initially termed as the B cell
differentiation factor) promotes B cell differentiation, and both
patients had reduced CD27positive memory B cells and reduced
class-switched memory B cells (Fig. 4 D).
Aspects of these patients’ clinical phenotype are shared by
patients with mutations in STAT3, IL6ST (Schwerd et al., 2017;
Shahin et al., 2019), or ZNF341 (Béziat et al., 2018; Frey-Jakobs
et al., 2018), which are part of a series of disorders associated
with IgE elevation (Table S1). ZNF341 deficiency leads to im-
paired STAT3 levels and signaling, primarily in the hematopoi-
etic compartment, and is associated with atopy, variable
elevation of IgE, and susceptibility to Candida and staphylococcal
infections. The similarities to the IL6ST-mutant patient are
greater, as the GP130-deficient patients presented with recur-
rent staphylococcal and streptococcal infections and a marked
reduction of an acute-phase response, but with eosinophilia and
elevation of their IgE. In addition, similar to IL-6R deficiency
described here, fungal infections were not a feature, in keeping
with diminished but present circulating Th17 cells seen in these
patients. However, like STAT3 LOF patients, the affected IL6ST
patients also demonstrated skeletal and connective tissue de-
fects, such as craniosynostosis and scoliosis, possibly caused by
GP130-dependent cytokines such as IL-11 (Schwerd et al., 2017).
The IL-6 link with the atopic phenotype of this group of patients
had been suggested by the association between common poly-
morphisms in the IL6R that diminish its function and increase
both levels of IgE (Wang et al., 2016) and susceptibility to asthma
(Ferreira et al., 2013). Furthermore, B cell–specific deletion of
STAT3 is sufficient to elevate serum IgE in mice (Kane et al.,
2016). The results from the IL-6R-LOF patients therefore clarify
the contribution of deficient IL-6 signaling to the phenotype of
patients with ZNF341, GP130, and STAT3-LOF mutations. This
includes elevated IgE, atopic dermatitis, and a susceptibility to
staphylococcal infections. This may indicate novel therapeutics
for the alleviation of these symptoms: for example, exogenous
recombinant soluble IL-6R could increase the presentation of IL-
6 to GP130.
Although results frommurine studies have suggested that IL-
6 signaling is an obligate necessity for a normal acute-phase
response, we have lacked confirmatory evidence for this in
Table 1. Immunological characteristics of patients
P1 P2
Age 6 yr Age 26 yr Age 14 yr
Absolute lymphocyte
count (×109/liter)
2.4 (1.1–4.5) 1.74 (1.1–4.5) 1.48 (1.1–4.5)
CD3+ T cells




































% 20 (6–25) 13.3 (6–25) 14 (6–25)
IgE (KU/liter) 859 (0–48) 7,060 (0–81) 795 (0–81)
IgG (g/liter) 4.5 (4.9–16.1) 7.71 (6–16) 5.3 (6–16)
IgG1 (g/liter) 4 (2.3–6.4)
IgG2 (g/liter) 0.28 (0.4–4.5)
IgG3 (g/liter) 0.78 (0.1–1.1)
IgG4 (g/liter) <0.02 (0–0.8)
IgM (g/liter) 0.5 (0.5–1.9) 0.24 (0.5–1.9) 0.3 (0.5–1.9)
IgA (g/liter) 0.3 (0.4–2.0) 0.91 (0.8–2.8) 0.6 (0.8–2.8)
Hib IgG (µg/ml) <0.15
(prevaccine)a
3.01a
Pneumococcal titer (IU/ml) 38b
Tetanus IgG (IU/ml) >0.1c
NBT (%) 0/96 100
DHR
Resting (%) 6 (Control, 2)
Stimulated (%) 100 (Control,
100)
IL-6 (pg/ml) 830.8 (0–7)
IL-6 (pg/ml) 205.6 (0–7)
Abnormal results are shown in bold. Numbers in parentheses indicate
reference values of the corresponding measurements. DHR,
dihydrorhodamine; Hib, H. influenza bacteria; NBT, nitroblue tetrazolium.
aMinimum protective level, 0.15 µg/ml; optimum protective level, 1.0 µg/ml.
bA value of 60 represents the 25th centile of the normal population.
cMinimum protective level, 0.01 IU/ml; optimum protective level, 0.1 IU/ml;
long-term protective level, >1.0 IU/ml.
Spencer et al. Journal of Experimental Medicine 1990






_20190344.pdf by guest on 12 N
ovem
ber 2020
Spencer et al. Journal of Experimental Medicine 1991






_20190344.pdf by guest on 12 N
ovem
ber 2020
humans. STAT3-LOF patients and GP130 patients have reduced
but detectable acute-phase proteins, including CRP (Freeman
and Holland, 2009; Schwerd et al., 2017), while patients with
anti–IL-6 autoantibodies, who present with skin infections
similar to the patients presented here, may also have other
neutralizing autoantibodies preventing CRP induction (Puel
et al., 2008). This report demonstrates that human CRP pro-
duction is directly dependent on IL-6 signaling and therefore
that a recordable CRP in a tocilizumab-treated patient indicates
incomplete IL-6 blockade. In addition to basic insights into in-
born errors of the IL-6/GP130/STAT3 axis, the patients de-
scribed in this report provide clear evidence for the scope of
potential side effects of IL-6 blockade. Furthermore, they high-
light the consequences of inborn loss of IL-6 signaling, corrob-
orating the intriguing observation that very early introduction
of tocilizumab (<2 yr of age), unlike in adults, is associated with
substantially increased immediate-type hypersensitivity re-
actions (Mallalieu et al., 2017).
Materials and methods
Detailed case history
P1 was born postterm after a normal pregnancy, to non-
consanguineous white English parents of European ancestry.
Her birthweight was 2.8 kg (9th–25th centile). She was admitted
for 2 wkwith apyrexial neonatal mastitis within the first month,
and within the first year of life she had suffered from multiple
infections, including impetiginized varicella and right and left
lower lobe pneumonias, and was noted to have painless lym-
phadenopathy. She received standard childhood vaccinations,
including diphtheria/tetanus/pertussis, polio, and measles/
mumps/rubella, without complications. She continued to grow
normally on height and weight centile charts, always above the
50th centile.
Having been managed initially by her local district general
hospital, she was referred to a specialist immunology service at
the age of 5 yr withH. influenza pneumonia associated with right
lower lobe collapse, and a right ear infection, which responded
to antibiotics. Nontender cervical and inguinal lymphadenopa-
thy was noted; biopsy of 6–10-mm inguinal lymph nodes dem-
onstrated reactive changes but was notable for an excess of
eosinophils, and cultures grew S. aureus. She responded to
treatment with i.v. flucloxacillin, and after this she was com-
menced antibiotic prophylaxis with cotrimoxazole 480 mg once
a day; however, purulent rhinitis and upper respiratory tract
symptoms persisted despite prophylaxis. She received H. influ-
enza B and pneumococcal vaccination (Pneumovax) at age 6
without complication. Antibodies to measles, mumps, rubella,
varicella, tetanus, and diphtheria were found to be present. On
the basis of her elevated IgE levels, a putative diagnosis of hyper-
IgE syndrome was given, with an National Institutes of Health
hyper-IgE syndrome score retrospectively calculated at 45.
However, IgE levels subsequently fluctuated and on a few
occasions were normal.
Over the following 12 yr, the patient continued to present
with recurrent sinopulmonary infections. A wheeze often ac-
companied chest symptoms, and she was started on steroid in-
halers after a diagnosis of asthma was established. Recurrent
otitis externa and otitis media eventually became chronic and
were associated with scarring of the tympanic membrane. She
also had two admissions with cellulitis requiring i.v. antibiotics.
It was noted that with episodes of infection, although she felt
systemically unwell, with nausea and vomiting, a recordable
fever was observed on only two occasions, throughout multiple
inpatient admissions for systemic infection. In addition, neu-
trophil response was blunted, and she did not generate a CRP
increase. Response to antibiotics tended to be slow or absent.
However, throughout this time she was found to be thriving and
missed very little school.
At the age of 11, she developed a severe pneumonia that was
complicated by a pleural effusion. Cultures from blood and
pleural fluid grew fully sensitive S. aureus; however, the
pleural fluid aspirated was notably lacking pus. Around this
time, she also began to develop occasional skin spots and skin-
colored nontender subcutaneous nodules, which were asso-
ciated with dermatitis and intense pruritus. Persistent
scratching led to the development of deeply excoriated craters
on thighs, buttocks, scalp, arms, and shoulders. Histology
obtained from biopsy of an eczematous lesion on the buttock
excluded vasculitis, granulomatous disease, or pemphigoid
but revealed an underlying eosinophil-rich inflammatory
dermatosis, severe enough to extend into the subcutaneous
fat, with flame figure formation. However, a definitive his-
topathological diagnosis could not be established. Skin and
nasal swabs routinely grew S. aureus, which was usually fully
sensitive, although methicillin-resistant S. aureus was grown
on several occasions. She has had multiple admissions with
cellulitis requiring i.v. antibiotics since childhood. She also
Figure 2. STAT signaling responses with and without ectopic expression of IL-6R in two patients with IL6Rmutations. (A) Left: Dot plots of GP130 and
CD45RO of gated CD3+CD4+ T cells from P1 and two healthy controls (HCs). Right: Dot plots of gp130 and CD27 of gated CD3+CD4+ T cells from P1.
(B) Fluorescence histograms of the indicated anti-pSTAT proteins’ expression in CD4+ T cells from healthy controls and P1 upon stimulation. (C) Fluorescence
histograms of the indicated anti-pSTAT proteins’ expression in CD4+ T cells from healthy controls and P2. (D) Left: Western blot of pSTAT3, STAT3, and actin
as a loading control in P1 and healthy control PBMCs stimulated with the indicated IL-6 concentration for 30 min. Right: Western blot of pSTAT3, STAT3,
pSTAT1, STAT1, and tubulin as a loading control in patient and healthy controls. PBMCs stimulated with the indicated cytokine concentrations for 30 min.
(E) Left: pSTAT3 in healthy controls’ and IL-6R–null (P1) CD4+ T cells, transfected with a vector expressing WT IL-6R at baseline and after IL-6 stimulation.
Right: The overlaid fluorescence histograms of pSTAT3 and pSTAT1 in PBMCs from the IL-6R–null patient in WT-IL-6R transfected and untransfected cells
stimulated with IL-6. (F) Bar graphs indicating relative mean fluorescence intensity (rMFI) of pSTAT1 and pSTAT3 upon IL-6 stimulation of HEK293 T cells
transfected with WT IL-6R, p.I279N/p.H280P IL6-R, p.I279N IL6-R, p.H280P IL6-R, or an empty vector (EV). Representative histograms are shown for each
condition. Data represent two replicates of three independent experiments (unpaired two-tailed Student’s t test done on mean of technical replicates; *, P <
0.05; **, P < 0.01). Error bars represent SEM.
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Figure 3. Immunophenotype of IL-6R–null patient. (A) Split dot plot visualizations of how gene expression varies in P1 and her healthy father (HP1)
generated from analysis of single-cell RNA-seq data from PBMCs. Top: Lineage defining transcription factor expression in memory CD4+ T cells. Bottom:
Expression of genes indicating state of B lymphocyte differentiation and immunoglobulin isotype class in B cells. The size of the dot corresponds to the
percentage of cells expressing the gene, and the color represents the average expression level. (B) GATA3 mRNA levels in ex vivo PBMCs isolated from P1 and
healthy controls (HCs), detected by real-time PCR. (C) Flow cytometry analysis of CD25+FOXP3+ cells of P1 and two healthy controls, gated on the
Spencer et al. Journal of Experimental Medicine 1993
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had occasional episodes of moderate, transient oral and vag-
inal candida, which occurred in association with antibiotic
treatment; however, she has never had disseminated or in-
vasive Candida infection.
Repeated attempts at prophylaxis with numerous antibiotics
were unsuccessful, although patient adherence may have been
unsatisfactory. Staphylococcal eradication therapy also failed.
She transitioned to adult care, but thereafter she was lost to
follow up between the ages of 18 and 26 yr.
She represented to immunology at the age of 26 yr, at which
point all her immunological tests were repeated. Notable ab-
normal results were significantly elevated IgE, eosinophilia,
absent mannose-binding lectin, and high levels of baseline IL-6
(830.8 pg/ml and 205.6 pg/ml on two samples; normal range,
0–7 pg/ml).
Further respiratory tract infections since representation
have been associated with growth of H. influenzae, Moraxella
catarrhalis, and Escherichia coli. She has had one episode of pe-
ripherally inserted central catheter line–associated sepsis, with
S. aureus grown from blood cultures and Proteus and S. aureus
cultured from the line tip. Skin lesions persisted and included
deep excoriations, subcutaneous nodules, and eczema, with
pruritus as a predominant symptom. In adulthood, she has had
recurrent admissions several times a year with painful swelling
of her left leg, shoulder, arm, and hand. Subcutaneous and
perifascial edema without collections are usually seen in the
limbs. Aspiration of the shoulder collection has been attempted,
but never successfully. More recently, she presented with re-
current mastitis and a lump in the left breast, which was felt to
be an abscess with associated ductal disease; on the penultimate
CD3+CD4+CD45RO+CD127− compartment. (D) Naive cells from healthy controls (n = 3) and P1 were cultured under the indicated Th17-inducing conditions for 6 d.
IL-17A, RORC, GATA3, and TBX21mRNA levels were detected by real-time PCR. (E) SOCS3mRNA levels of naive cells from P1 and healthy controls activated by
the indicated cytokines for 18 h. Error bars represent SEM.
Figure 4. Immunophenotype of patients with IL6R mutations. (A) Percentages of IL-17A–producing (left) and IFNγ-producing (right) CD4+ T cells from
healthy controls (HCs; n = 5), P1 (dark square), and P2 (blue circle) from two independent experiments. Black, data from experiment 1; blue, data from ex-
periment 2. (B) Flow cytometry analysis of expression of markers found in pathological effector Th2 cells in CRTH2+ memory CD4+ T cells. Mann–Whitney U
test; *, P < 0.05. (C) Flow cytometry analysis of blood CXCR5+ memory cTFHs in P1, P2, and healthy controls. (D) Flow cytometry assessment of B lymphocyte
class switching and memory cell formation in P1, P2, and healthy controls and the healthy parents (HP). Error bars represent SEM.
Spencer et al. Journal of Experimental Medicine 1994
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episode, 8 ml of pus growing S. aureus was aspirated from an
abscess inferior to the left lateral malleolus, showing that pus
formation is not completely absent. The most recent episode was
of severe cellulitis of the entire left leg, with pain, erythema,
marked swelling, and edema involving the subcutis down to and
including the fascial plane on magnetic resonance imaging,
showing that erythema is not completely absent; however, the
patient remained apyrexial with undetectable CRP throughout.
Clinical studies
The NBR-RD study was established in the UK to further the
clinical management of patients with rare diseases by providing
a national resource of WGS data. Written informed consent
was obtained from the patients and their relatives or healthy
normal donors, in accordance with the principles of the ethics
committees of the Institutional Review Boards of the Medical
University of Vienna (EK-Nr:499/2011) and the East of
England–Cambridge South National Institutional Review Board
(13/EE/0325).
Genetic analysis
For P1, WGS was performed by Illumina. The sample was frag-
mented to 450-bp fragments, processed with the Illumina Tru-
Seq DNA PCR-Free Sample Preparation kit, and sequenced using
150-bp reads on a single HiSeqX lane. The delivered genome had
a minimum 15× coverage over ≥95% of the reference autosomes.
Illumina performed the alignment to GRCh37 genome build and
calling of variants <50 bp in length using Isaac software, while
large deletions were called with Manta and Canvas algorithms.
TheWGS data files were received at the University of Cambridge
High Performance Computing Service for further in-house
quality control and processing. The analyses presented here
are based on single nucleotide variants (SNVs) and indels
(<50 bp long) with overall pass rate (OPR) >0.98 across
13,037 in-house NBR-RD genomes, and high-confidence deletion
calls. Variants were annotated with Sequence Ontology terms
according to their predicted consequences; their frequencies in
other genomic databases (gnomAD, UK10K, 1000 Genomes), if
they have been associated with a disease according to the Hu-
man Gene Mutation Database Pro database; and internal metrics
(allele number, allele count, allele frequency [AF], and OPR).
For assessment of ancestry, relatedness, and loss of hetero-
zygosity, a set of reliably genotyped, unlinked SNVswere chosen
as follows: 292,878 autosomal SNVs typed by three widely used
Illumina genotyping arrays were filtered to exclude those with
at least one missing genotype in the NBR-RD 13,037 genomes or
OPR <0.99; more than two alleles in the 1000 Genomes Phase 3
or NBR-RD datasets; and minor AF (MAF) <0.3 in NBR-RD. Fi-
nally, after pruning with PLINK so that all pairs of SNVs had
r2 <0.2, we were left with 32,875 SNVs to be used for further
analyses. Ancestry relative to 1000 Genomes populations was
estimated by performing principal component analysis. PC-
Relate R package and the same set of SNVs were used to gen-
erate overall proportion of genome-wide homozygosity, as well
as pairwise kinship coefficients that allowed us to compute a
maximal unrelated sample set for the purposes of internal AF
estimation. A denser set of SNVs (all with OPR >0.98 and
internal AF >0.5%) and bcftools roh tool were used to compute
the exact regions displaying loss of heterozygosity, which were
found to span the entire C1 and account for the total homozy-
gosity in this sample. The plot in Fig. 1 D is based on a subset of
23,368 SNVs that had nonreference genotype calls in P1 and was
generated using ggbio R package (Yin et al., 2012). Non-
synonymous and splice-site SNVs and indels on C1 were filtered
based on gnomAD AFs <0.001 and CADD score >20. Resulting
variants are listed in Table S2, and the one in the IL6R was
prioritized based on clinical presentation. We did not identify
any rare large deletions or rare coding homozygous compound
heterozygous SNVs and indels outside of C1.
For P2, whole-exome sequencing was performed using the
TrueSeq Rapid Exome kit, Illumina HiSeq3000 system, and the
cBot cluster generator. Burrows-Wheeler Aligner was used to
align reads against version 19 of the human genome as a refer-
ence. Insertion-deletion realignment was performed as well as
recalibration based on Genome Analysis Toolkit quality scores.
To call SNVs and deletion-insertion variants, UnifiedGenotyper
and Genome Analysis Toolkit Variant quality score recalibration
was performed as described previously with minor mod-
ifications. Generated lists of SNVs and deletion-insertion var-
iants were annotated with SNPEFF. Variants present in 1000
Genomes Project and/or gnomAD datasets with MAF ≥0.01 were
excluded from further analyses. An internal database of >2,000
exomes was also used to filter out recurrent variants. In the
resulting list of variants, under the assumption of autosomal
recessive inheritance, homozygous changes were then subjected
to prioritization using the SIFT, PolyPhen-2, and CADD tools to
assess in silico the effect of the identified mutations (Table S2).
All of the variants identified in IL6R gene of P2 were plotted in
the CADD/MAF graph, including the population variants ex-
tracted from ExAC and gnomAD databases (Fig. 1 D).
Next-generation sequencing data are deposited at the Euro-
pean Genome-phenome Archive, which is hosted by the Euro-
pean Bioinformatics Institute and the Centre for Genomic
Regulation, under accession IDs EGAD00001005051 (P1) and
EGAS00001003675 (P2). The data are accessible through the
relevant Data Access Committee via formal application at the
European Genome-phenome Archive.
For P1, Sanger confirmation was performed using primers
(forward, 59-TGTCCCGTCTTGAGTCTGTG-39; reverse, 59-TGC
TTTATCATTGCCACACC-39) that amplified a 364-bp fragment
spanning exon 4 of the IL-6R gene. For P2, forward, 59-GGGGCA
GGGACTTTCTGC-39, and reverse, 59-GTACTGCGGTGGGCACTG
A-39, primers were used to amplify exon 6.
Single-cell RNA-seq
Single-cell RNA-seq libraries were prepared in the Cancer Re-
search UK Cambridge Institute Genomics Core Facility using the
following: Chromium Single Cell 59 Library & Gel Bead Kit, PN-
1000006; Chromium Single Cell A Chip Kit, PN-1000009;
Chromium i7 Multiplex Kit, PN-120262; Chromium Single Cell
V(D)J Enrichment Kit, Human B Cell, PN-1000016; Chromium
Single Cell V(D)J Enrichment Kit, Human T Cell, PN-1000005;
and the Single-Cell V(D)J Reagent Kits User Guide (Manual Part
CG000086 Rev J; 10X Genomics).
Spencer et al. Journal of Experimental Medicine 1995
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Cell suspensions of both samples were resuspended in PBS-
0.04% BSA and loaded into Chromium microfluidic chips with
10X Genomics 59 V(D)J and gene expression chemistry to
generate single-cell gel-bead emulsions using the Chromium
controller (10X Genomics) according to the manufacturer’s
recommendations. Suspensions containing ∼16,000 cells were
loaded on the instrument with the expectation of collecting up to
9,000 gel-bead emulsions containing single cells (expected
multiplet rate ∼7%). RNA from the barcoded cells for each
sample was subsequently reverse-transcribed in a T100 Thermal
cycler (Bio-Rad), and all subsequent steps to generate single-cell
libraries were performed according to the manufacturer’s pro-
tocol with no modifications, with 14 cycles used for cDNA am-
plification. Then ∼50 ng of cDNA was used for gene expression
library amplification by 14 cycles in parallel with cDNA enrich-
ment and library construction for T and B cell libraries.
Library quality was confirmed with Agilent TapeStation
4200 (High Sensitivity D1000 ScreenTape to evaluate library
sizes) and BMG LABTECH Clariostar Monochromator Micro-
plate Reader (Invitrogen Quant-iT dsDNA Assay Kit; high
sensitivity to evaluate dsDNA quantity). Each sample was
normalized to equal molar concentration and pooled in the fol-
lowing ratio: 90% gene expression library, 5% human B cell
library, 5% human T cell library. Samples were sequenced on an
Illumina HiSeq 4000 as 2 × 150 paired-end reads, one full lane
per pool (before analysis, gene expression data were trimmed to
26 bp, read 1; 8 bp, i7 index; and 98 bp, read 2).
Using the 10X Genomics Single Cell Immune Profiling solu-
tion, we obtained single cell V(D)J measurements and 59 gene
expressions for both P1 and her healthy father. To find the
shared correlation structure of the combined father and P1
normalized and scaled gene expression matrices, we used ca-
nonical correlation analysis (Butler et al., 2018). The two data-
sets were then aligned using a dynamic time-warping algorithm
as implemented in the Seurat R package (https://CRAN.R-
project.org/package=Seurat). We then performed clustering on
all the cells using a shared nearest neighbor modularity
optimization–based clustering algorithm (Xu and Su, 2015).
By merging the gene expression data with the V(D)J counts,
we were able to annotate TCR- and B cell receptor–bearing cells
and to identify cell types, which clusters were memory CD4+
T cells, and which were B cell clusters. We confirmed this by
examining cell type marker genes that were conserved between
samples in each cluster.
RNA-seq data for P1 and her healthy father have been de-
posited in the ArrayExpress database at European Molecular
Biology Laboratory/European Bioinformatics Institute under
accession no. E-MTAB-8034.
PAGE and Western blot analysis
Protein lysates were separated by SDS-PAGE and transferred
onto a nitrocellulose membranes. Individual proteins were de-
tected with antibodies against STAT3 (clone 124H6), STAT1
(clone 9H2), pSTAT3 (clone D3A7), pSTAT1 (clone D4A7), and
β3-Tubulin (D65A4; Cell Signaling Technology). Secondary an-
tibodies were either goat anti-mouse-IgG IRDye 680CW or
goat anti-rabbit-IgG IRDye 800CW (LI-COR Biosciences).
Quantification of bound antibodies was performed on an Od-
yssey Infrared Imaging system (LI-COR Biosciences).
Flow cytometry analysis
For intracellular cytokine detection, cells were stimulated with
20 ng/ml PMA and 1 µM ionomycin for 5 h. 10 µg/ml brefeldin A
was added after 2.5 h. Cells were then fixed and permeabilized
with Cytofix/Cytoperm (BD Biosciences) per the manufacturer’s
protocol and stained with Live/Dead Fixable Aqua dye, CD3
AF700, CD4 BUV395, IL-17F AF488, IFNγ fluorescein v450, IL-4
PE-Cy7 (BD Biosciences), CD45RO ECD (Beckman Coulter), and
IL-17A PE and IL-21 e660 (eBiosciences). For P2, we conducted
the same procedure with the following antibodies: CD3 APCH7,
CD8 V500, CD45RA AF700, CD25 PE, IL4 APC, CD197 PE-CF594
(BD Biosciences), CD4 PCy7 (Beckman Coulter), IFNγ FITC, Il17A
eFluor450 (eBiosciences), and CCR6 BV605 (Biozym Scientific).
Intracellular pSTAT analysis was previously described in Shahin
et al. (2019). Regulatory T cell staining was based on the eBio-
science FOXP3 intracellular staining reagents and protocol.
Other intracellular staining was done by fixation in PFA fol-
lowed bymethanol permeabilization. Additional antibodies used
for flow cytometry analysis: IL-6R PerCP-Cy5.5 (BioLegend),
CRTH2 AF647 (BD Biosciences), CCR6 BV421 (BD Biosciences),
CXCR3 PE-Cy7 (BioLegend), CCR4 BV605 (BioLegend), CD27
BV650 (BioLegend), CCR7 BV711 (BioLegend), CD49d BV510
(BioLegend), CD161 FITC (BioLegend), CD7 PerCP-Cy5.5
(BioLegend), CD45RO ECD (Beckman Coulter), and Live/Dead
Fixable Blue (Life Technologies). Additional antibodies used for
P2: IL6R PE (BD Biosciences), CD7 PerCPCy5.5 (BD Biosciences),
CD161 FITC (BD Biosciences), CD45RO AF700 (BD Biosciences),
CRTH2 AF647 (BD Biosciences), CXCR3 BV711 (BioLegend), CCR6
BV605 (BioLegend), CD4 V500 (BD Biosciences), CD27 V450 (BD
Biosciences), CCR4 PeCy7 (BD Biosciences), CCR7 PE-CF594 (BD
Biosciences), and CD49d PE (BD Biosciences).
Real-time PCR
To assay SOCS3 up-regulation in response to cytokine stimula-
tion, naive CD4 T cells were stimulated with or without IL-6
(100 ng/ml; Peprotech), IL-21 (100 ng/ml; Peprotech), IL-23
(100 ng/ml; R&D Systems), or IL-27 (50 ng/ml; R&D Systems)
for 18 h. Cells were then washed and pelleted. Total RNA was
extracted from PBMCs with the RNeasy Mini Kit (Qiagen). For
real-time PCR, 1 µg of total RNA was reverse transcribed (In-
vitrogen), and the resulting cDNA was amplified by means of
PCR with the ABI 7500 Sequencer and TaqMan expression as-
says (Applied Biosystems). 18S was used as a normalization
control. The data were analyzed with the 2−ΔΔCT method, and
results are expressed as mean fold induction.
Th17 differentiation
Naive CD4+ T cells were isolated from PBMCs using negative
selection magnetic-activated cell sorting microbeads (Miltenyi
Biotec) per the manufacturer’s protocol. Purity was >95% in all
samples run. For T cell differentiation, cells were stimulated at
100,000 cells/well in 96-well flat-bottom plates that had been
coated with anti-CD3 (10 µg/ml; OKT3 eBioscience) antibodies.
The cells were cultured in X-VIVO 15medium at 37°C/5% CO2 for
Spencer et al. Journal of Experimental Medicine 1996
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6 d in the presence of soluble anti-CD28 (0.5 ug/ml; BD Phar-
Mingen). For Th17, anti-IFNγ (10 µg/ml; BD PharMingen) and
IL-1β (10 ng/ml; Peprotech) were added to all the groups, and
IL-23 (100 ng/ml; R&D Systems), IL-6, and IL-21 (both 20 ng/ml;
Peprotech) were also added as indicated. For Th0, 100 U/ml
IL-2 (R&D Systems) was added.
Transfection of PBMCs
PBMCs from P1 and healthy volunteers were nucleofected with
pcDNA3.1+/C-(K)-DYK plasmid DNA expressing WT IL-6R using
a human T cell nucleofector kit (VPA-1002; Lonza) according to
the manufacturer’s protocol for unstimulated human T cells
(program V-024). Cells were cultured in T cell medium (RPMI
1640 supplemented with 2 mM L-glutamine and 10% FBS)
overnight before assays, transfected T cells expressingWT IL-6R
were identified as Flag+ cells by anti-Flag antibody staining.
Transfection of HEK293T cells
HEK293T cells were plated on 96-well flat-bottom plates and
transfected with pcDNA3.1+/C-(K)-DYK plasmid DNA express-
ing WT IL-6R, p.I279N/p.H380P IL-6R, p.I279N IL-6R, p.H280P
IL-6R, or an empty plasmid using the Effectene reagent (Qiagen)
according to the manufacturer’s protocol. Cells were cultured in
DMEM (10% FBS and 2mM L-glutamine) and incubated over-
night. Transfected cells were then starved for 3 h in serum-free
DMEM followed by the pSTAT assay described above.
Online supplemental material
Fig. S1 shows an assessment of IL-6R expression in cells ec-
topically expressing IL-6R or IL-6R mutants. Fig. S2 shows
t-distributed stochastic neighbor embedding (tSNE) projec-
tions of the IL-6R–null patient and her father’s PBMCs. Fig. S3
shows ex vivo FACS assessment of T cell differentiation in P1
and healthy controls. Table S1 compares clinical features of
patients with IL6R mutations and other patient cohorts with
defined gene defects presenting with elevated IgE. Table S2
lists homozygous nonsynonymous variants in P1 and P2
identified by WGS.
Acknowledgments
We thank all volunteers for their participation, and also grate-
fully acknowledge NIHR Biomedical Research Centres, NIHR
BioResource Centres, National Health Service (NHS) Trust
Hospitals, NHS Blood and Transplant and staff for their
contribution.
J.E.D. Thaventhiran is supported by the Medical Research
Council (RG95376 andMR/L006197/1). K. Boztug is supported by
the European Research Council (ERC StG 310857) and the Aus-
trian Science Fund (P29951-B30). This work is supported, in
part, by the intramural research program of the National Insti-
tute of Allergy and Infectious Diseases, NIH (1ZIAAI001098-02).
A.J. Thrasher is supported by the Wellcome Trust (104807/Z/14/Z)
and the NIHR Biomedical Research Centre at Great Ormond
Street Hospital for Children NHS Foundation Trust, and Uni-
versity College London. K.G.C. Smith is supported by the
Medical Research Council (program grant MR/L019027) and is
a Wellcome Investigator. M. Gürel and S. Tavaré are supported
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